DB12161

GPTKB entity

Statements (44)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2020
gptkbp:approvedBy gptkb:COVID-19
gptkbp:ATCCode J05AB16
gptkbp:CASNumber 1809249-37-3
gptkbp:chemicalStructureType antiviral drug
gptkbp:contraindication hypersensitivity to remdesivir
gptkbp:countryOfOperation gptkb:European_Union
gptkb:United_States
gptkbp:developedBy gptkb:Gilead_Sciences
gptkbp:drugClass antiviral drug
gptkbp:eliminationHalfLife 1 hour (parent), 25 hours (metabolite)
gptkbp:hasInChIKey RWWYLEGWBNMMLJ-YSOARWBDSA-N
gptkbp:hasMolecularFormula C27H35N6O8P
gptkbp:hasPatent US20170071964A1
WO2017089063A1
gptkbp:hasSMILES CC(C)[C@@H](NC(=O)[C@@H](COP(=O)(OCC1=CN=CN1)OCC2=O)N)C(=O)N[C@@H](C)C(=O)O
gptkbp:hasUNII 53J0A3T2V9
https://www.w3.org/2000/01/rdf-schema#label DB12161
gptkbp:indication treatment of COVID-19
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction RNA polymerase inhibitor
gptkbp:metabolism primarily hepatic
gptkbp:molecularWeight 602.6 g/mol
gptkbp:name gptkb:Remdesivir
gptkbp:pregnancyCategory Not assigned
gptkbp:prodrugOf gptkb:GS-441524
gptkbp:proteinBinding 88-93%
gptkbp:PubChem_CID gptkb:DB12161
121304016
CHEMBL2016761
D11472
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect nausea
elevated liver enzymes
hypersensitivity
gptkbp:status approved
gptkbp:storage store below 30°C
gptkbp:synonym gptkb:Veklury
gptkb:GS-5734
gptkbp:target RNA-dependent RNA polymerase
gptkbp:bfsParent gptkb:dupilumab
gptkb:Dupilumab
gptkbp:bfsLayer 7